XTX Topco Ltd bought a new position in OptimizeRx Co. (NASDAQ:OPRX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 36,674 shares of the company's stock, valued at approximately $178,000. XTX Topco Ltd owned 0.20% of OptimizeRx as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in OPRX. Whetstone Capital Advisors LLC purchased a new position in shares of OptimizeRx in the fourth quarter worth $6,563,000. Royce & Associates LP purchased a new stake in OptimizeRx during the 4th quarter valued at $5,198,000. Kennedy Capital Management LLC lifted its stake in OptimizeRx by 57.8% in the fourth quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company's stock worth $2,887,000 after purchasing an additional 217,676 shares during the last quarter. JPMorgan Chase & Co. boosted its position in OptimizeRx by 670.3% in the 4th quarter. JPMorgan Chase & Co. now owns 59,952 shares of the company's stock valued at $291,000 after buying an additional 52,169 shares during the period. Finally, AMH Equity Ltd lifted its holdings in shares of OptimizeRx by 25.0% in the 4th quarter. AMH Equity Ltd now owns 125,000 shares of the company's stock worth $608,000 after buying an additional 25,000 shares during the period. 76.47% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research firms recently commented on OPRX. JMP Securities reiterated a "market outperform" rating and issued a $8.00 target price on shares of OptimizeRx in a research note on Thursday, February 6th. Royal Bank of Canada reissued a "sector perform" rating and issued a $6.00 target price (down from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Finally, B. Riley upgraded shares of OptimizeRx to a "strong-buy" rating in a report on Wednesday, March 12th. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $9.06.
Get Our Latest Research Report on OptimizeRx
OptimizeRx Stock Performance
OPRX stock traded up $0.41 during midday trading on Friday, hitting $10.05. The stock had a trading volume of 223,791 shares, compared to its average volume of 268,257. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $185.85 million, a price-to-earnings ratio of -7.56 and a beta of 1.28. OptimizeRx Co. has a 52 week low of $3.78 and a 52 week high of $14.13. The stock has a 50-day simple moving average of $7.69 and a 200 day simple moving average of $6.19.
Insider Activity
In other OptimizeRx news, Director James Paul Lang purchased 321,408 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were acquired at an average cost of $7.60 per share, with a total value of $2,442,700.80. Following the completion of the transaction, the director now owns 389,452 shares in the company, valued at $2,959,835.20. The trade was a 472.35 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.10% of the stock is currently owned by company insiders.
OptimizeRx Company Profile
(
Free Report)
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Featured Stories
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
